See what’s changing first. Know which accounts matter next.
Fundz catches funding rounds before they’re announced, and acquisitions, new executives, hiring shifts and contract wins as they happen. It weighs them against your ideal customer profile and delivers a ranked shortlist every morning, with the evidence, the reason to reach out and the decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Parabilis Medicines goes public with a record-setting IPO of $770 million led by Sixty Degree Capital. This marks another successful exit for SDC's portfolio in 2026.
Parabilis Medicines has successfully completed an initial public offering, raising $770 million. This offering is noted as the largest biotech IPO in history, representing a significant milestone for the company and its investors. Sixty Degree Capital continues to support its portfolio companies through successful exits. The public listing marks a new chapter for Parabilis as it scales its operations.
Company Information
Company
Parabilis Medicines
Location
Cambridge, Massachusetts, United States
About
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors.
Fundz sees it the moment Parabilis Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma